Ternium S.A. (TX) Stock News

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether the boards of MarketAxess Holdings, CBIZ, Sanara MedTech, and TriCo Bancshares breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The firm is seeking shareholders to discuss potential class action lawsuits.

Syntec Optics (NASDAQ: OPTX) announced a major production order to expand its space optics product line, focusing on advanced collision avoidance systems for satellites in low Earth orbit. The company will manufacture specialized optics to help satellites detect and avoid space debris traveling at extreme speeds. Syntec leverages its existing expertise in high-precision optics manufacturing and satellite communication systems to address the growing space traffic management challenge.

HTX completed its inaugural TradFi 'Trade to Earn' campaign, generating 63.37 million USDT in trading volume with up to 110% fee rebates. The campaign distributed 23,477 USDT in rewards while saving users 22,238 USDT in fees. Trading fees were allocated to buy back and burn $HTX tokens, linking platform growth to token value creation. HTX plans to launch a second phase with expanded TradFi asset access.

Vanguard's VDC and First Trust's FTXG are both defensive ETFs investing in consumer staples, but with different approaches. VDC offers broader diversification across 103 stocks with a lower 0.09% expense ratio and stronger 5-year returns, while FTXG concentrates on 30 food and beverage companies with a higher 2.59% dividend yield but higher 0.60% expense ratio. For most long-term investors, VDC is the more straightforward choice due to lower costs and better diversification.

Lockheed Martin, RTX lift 2026 forecasts as Pentagon looks to restock weapons  Reuters

SINTX Technologies has engaged Southern Metrics Consulting, led by veteran MedTech executive Chris Lyons (who serves on SINTX's Board since April 2025), to establish a Strategic Opportunity Management Program. The program will identify and evaluate strategic opportunities including partnerships, licensing, investments, joint ventures, and acquisitions to enhance stockholder value as the company transitions from development to commercial-stage operations.

Syntec Optics Holdings, Inc. (NASDAQ: OPTX), a high-precision optics and photonics manufacturer based in Rochester, New York, has been included in the Russell 3000® Index effective June 29, 2026. The inclusion provides the company with increased visibility and credibility among major investment funds and institutional investors globally.

21Shares announced a 1-for-10 reverse share split for its 21Shares 2x Long Sui ETF (TXXS) effective July 6, 2026. The structural adjustment reduces outstanding shares by 90% while proportionally increasing per-share NAV and market price. Shareholder total investment value remains unaffected by the split.

Syntec Optics (Nasdaq: OPTX) announced it received nearly $4 million in U.S. life sciences purchase orders for biomedical optical products, including applications in surgical robotics, DNA sequencing, and ophthalmology. This follows a previously announced $4.6 million order for laser blood analysis optics, demonstrating the company's expanding role in critical healthcare infrastructure.

The article compares two major defense contractors: Lockheed Martin, which relies heavily on the F-35 program and U.S. government contracts (72% of sales), and RTX, which offers more diversification through commercial and military aerospace segments. Lockheed Martin is recommended as the better buy due to lower valuation multiples (forward P/E of 17x vs. RTX's 26.7x) and guaranteed long-term revenue from the F-35 program extending into the 2040s, despite RTX showing faster expected growth and lower debt levels.

Aditxt Inc. (NASDAQ:ADTX) shares fell 33.94% in after-hours trading on Tuesday following an SEC Form 4 filing disclosing that major shareholder HRT Financial LP purchased 4.25 million shares at $0.016 per share on June 12. Despite the insider purchase, the stock continued to face selling pressure, closing the regular session down 15.50% at $0.011 before declining further to $0.0072 after hours. The stock has lost nearly 100% of its value over the past 12 months and hit a 52-week low of $0.0090.

The Invesco KBW Bank ETF (KBWB) and First Trust Nasdaq Bank ETF (FTXO) both provide exposure to the U.S. banking sector but differ in strategy and performance. KBWB offers lower fees (0.35% vs 0.6%), higher dividend yield (2.0% vs 1.8%), and better long-term returns (12.6% CAGR vs 9.8%), while FTXO provides broader diversification with 42 holdings versus KBWB's 26. Both have underperformed the S&P 500.

Confo Therapeutics presented preclinical data for CFTX-2034, an SSTR5 agonistic antibody candidate for post-bariatric hypoglycemia (PBH), at ENDO 2026. The data demonstrate dose-dependent suppression of insulin and GLP-1 secretion, selective pharmacology, and a long half-life supporting once-monthly dosing. The company plans to advance CFTX-2034 through IND-enabling studies toward Phase 1 clinical development.

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.

A comparison of two defensive equity ETFs reveals that iShares U.S. Consumer Staples ETF (IYK) outperforms First Trust Nasdaq Food & Beverage ETF (FTXG) with lower expenses (0.38% vs 0.60%), higher 5-year returns ($1,364 vs $955 on $1,000 invested), and broader sector exposure. While FTXG offers a niche food and beverage focus, IYK's superior performance and lower costs make it the more attractive option for conservative investors.

SpaceX's upcoming IPO values the company at $1.77 trillion, exceeding the combined valuation of all 12 S&P 500 aerospace and defense companies (~$1.5 trillion), despite generating only $18.7 billion in revenue compared to their $500 billion combined. While analysts like Gene Munster and Ron Baron express bullish sentiment with predictions of $30 trillion future value, critics including NYU's Aswath Damodaran raise concerns about valuation and market opportunity estimates.

Nvidia unveiled the RTX Spark, a superchip combining Blackwell RTX graphics, Arm CPU cores, and an NPU for personal computers, marking the company's entry into the PC market. The chip delivers petaflop AI computing power and unified memory for local AI applications. Analysts view this as part of Nvidia's broader strategy to dominate AI across all layers—data centers, edge, PCs, and IoT—with strong revenue growth expected and price targets reaching $500 within 12 months.

ASUS unveiled its new ProArt P16 and P14 laptops along with a ProArt Mini PC powered by NVIDIA's RTX Spark superchip at Computex 2026. These devices are designed for AI creators and developers, featuring up to 1 petaflop of AI performance, 128GB unified memory, and ASUS Lumina Pro OLED displays. The ecosystem integrates exclusive AI tools and partnerships with Adobe, Blackmagic Design, and Blender. Availability begins fall 2026.

Xage Security announced integration with NVIDIA's new DOCA security capabilities and Vera BlueField-4 STX to deliver line-speed policy enforcement and visibility for AI factories. The combined solution enables Zero Trust security for autonomous AI agents across APIs, databases, and applications while maintaining AI performance without modifying host software.

HP Inc. unveiled a comprehensive portfolio of AI-enabled devices and solutions designed for developers, creators, and gamers. The announcement includes laptops powered by NVIDIA RTX Spark, the HP OmniDesk Mini Desktop PC with Thunderbolt Share, secure AI processing systems for regulated environments, and workstations featuring AMD Ryzen AI PRO processors. These devices aim to accelerate local AI processing and hybrid workflows while maintaining security and ease of setup.

MediaTek and NVIDIA announced a collaboration on the RTX Spark, a new processor class for Windows 11 PCs designed for personal AI agents, content creation, and gaming. MediaTek contributes CPU performance, power efficiency, memory architecture, and connectivity expertise, while NVIDIA provides its AI platform and RTX technologies. The first RTX Spark-powered laptops will launch in Fall 2026, marking MediaTek's expansion from entry-level devices into the premium Windows PC market.

NVIDIA announced new security innovations for Vera BlueField-4 STX, introducing enhanced DOCA Vault, Argus, and Flow capabilities designed to protect agentic AI systems. The platform delivers runtime threat detection up to 1,000x faster than existing solutions while enforcing network and file access policies at speeds up to 800Gb/s. Multiple cybersecurity and storage partners are integrating with the platform, with availability expected in H2 2026.

Suntex Enterprises (OTC: SNTX) announced that its subsidiary Red Spur Land & Ranch Co. is in advanced negotiations to acquire approximately 100 acres in Texas for a large-scale residential and commercial development project. The company plans to leverage its vertically integrated subsidiaries including JA Development & Construction, Deep South Electrical Contractors, and Golden Era Development to execute the multi-phase project, aiming to strengthen operational efficiencies and long-term asset value creation.

Suntex Enterprises announced that its subsidiary Red Spur Land & Ranch Co. is in advanced negotiations to acquire approximately 100 acres in Texas for a large-scale residential and commercial development project. The company plans to leverage its vertically integrated subsidiaries including JA Development & Construction, Deep South Electrical Contractors, and Golden Era Development to execute the multi-phase project. Management emphasizes this reflects their long-term strategy of building enterprise value through integrated operations, though negotiations remain ongoing with no assurances of completion.

BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.

Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.

China banned Nvidia's RTX 5090D V2 chip, signaling a shift toward reducing dependency on U.S. semiconductors and favoring domestic alternatives. While the U.S. approved H200 sales to Chinese tech companies, no chips have been delivered due to undisclosed conditions from Beijing. Nvidia's China revenue has fallen to 5% of total sales, and the ban suggests the company's export-compliant strategy has failed at both ends—Washington restricts high-end chips while Beijing blocks lower-end alternatives.

Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.

Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.